ArticleDiabetes, obesity & metabolism2026
GLP-1 Receptor Agonists and Risk of Skin Cancer in Adults With Type 2 Diabetes: A Target Trial Emulation.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GLP-1 Receptor Agonists and Risk of Skin Cancer in Adults With Type 2 Diabetes: A Target Trial Emulation.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsExisting evidence regarding the association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and risk of melanoma and non-melanoma skin cancer (NMSC) is inconclusive. This study aimed to assess the association between GLP-1RA initiation and risks of melanoma and NMSC versus sodium-glucose cotransporter 2 inhibitors (SGLT2is) and dipeptidyl peptidase 4 inhibitors (DPP4is) in adults with type 2 diabetes (T2D). MATERIALS AND
methodsTarget trial emulation using TriNetX electronic health records (2014-2025). Adults with T2D initiating GLP-1RAs, SGLT2is or DPP4is were included. Outcomes were incident melanoma and NMSC over 3 years. Propensity score matching and Cox models estimated hazard ratios (HRs). Sensitivity analyses included negative control outcome (NCO) calibration, a lag-period analysis and restriction to patients with obesity.
resultsAfter matching, the GLP-1RA versus SGLT2i cohort included 235 797 pairs; the GLP-1RA versus DPP4i cohort included 153 873 pairs. Mean follow-up ranged from 1.8 to 2.2 years. GLP-1RA use was not associated with melanoma compared with either SGLT2i (HR, 1.04; 95% CI, 0.93-1.17) or DPP4i (HR, 1.09; 95% CI, 0.95-1.25). A borderline increase in NMSC risk was observed in the comparison with SGLT2is (HR, 1.06; 95% CI, 1.00-1.11); no such association was identified in the comparison with DPP4is (HR, 1.03; 95% CI, 0.97-1.09). Findings were generally consistent across sensitivity analyses; however, the association with NMSC was attenuated after NCO calibration.
conclusionsGLP-1RA therapy was not associated with an increased risk of melanoma. A borderline increase in NMSC risk was observed compared with SGLT2is but was not evident after NCO calibration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.